EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Iron deficiency and the effectiveness of the BNT162b2 vaccine for SARS-CoV-2 infection: A retrospective, longitudinal analysis of real-world data

Lilac Tene, Avraham Karasik, Gabriel Chodick iD, Dora I A Pereira, Henrik Schou, Sandra Waechter, Udo-Michael Göhring, Hal Drakesmith

PLOS ONE · 2023

DOI: 10.1371/journal.pone.0285606 ↗

Kurz gefasst

Fachartikel in der Zeitschrift PLOS ONE, 2023. Verfasst von Lilac Tene und 7 weiteren Autor:innen. Beteiligte Einrichtung: Maccabi Institute for Research & Innovation, Maccabi Healthcare Services, Tel Aviv, Israel. Hauptthemen laut MEDLINE: COVID-19, Vaccines, Iron Deficiencies. Die Arbeit wurde bisher 8-mal zitiert (Crossref) und nennt 32 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Medical Research Council, Vifor Pharma.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Iron plays a key role in human immune responses; however, the influence of iron deficiency on the coronavirus disease 2019 (COVID-19) vaccine effectiveness is unclear.

Aim

To assess the effectiveness of the BNT162b2 messenger RNA COVID-19 vaccine in preventing severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection and COVID-19–related hospitalization and death in individuals with or without iron deficiency.

Methods

This large retrospective, longitudinal cohort study analyzed real-world data from the Maccabi Healthcare Services database (covering 25% of Israeli residents). Eligible adults (aged ≥ 16 years) received a first BNT162b2 vaccine dose between December 19, 2020, and February 28, 2021, followed by a second dose as per approved vaccine label. Individuals were excluded if they had SARS-CoV-2 infection before vaccination, had hemoglobinopathy, received a cancer diagnosis since January 2020, had been treated with immunosuppressants, or were pregnant at the time of vaccination. Vaccine effectiveness was assessed in terms of incidence rates of SARS-CoV-2 infection confirmed by real-time polymerase chain reaction assay, relative risks of COVID-19–related hospitalization, and mortality in individuals with iron deficiency (ferritin

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

COVID-19VaccinesIron DeficienciesAdultPregnancyHumansFemaleMaleCOVID-19 VaccinesBNT162 VaccineRetrospective StudiesLongitudinal StudiesSARS-CoV-2

Substanzen

COVID-19 VaccinesBNT162 VaccineVaccines

Autor:innen und Institutionen

  • Maccabi Institute for Research & Innovation, Maccabi Healthcare Services, Tel Aviv, Israel.
  • CSL Vifor, Glattbrugg, Switzerland.
  • Medical Research Council Human Immunology Unit, MRC Weatherall Institute of Molecular Medicine, University of Oxford, Oxford, United Kingdom.

ORCID-Profile: Gabriel Chodick

Förderung

  • Medical Research Council
  • Vifor Pharma

Zitieren

APA

Tene, L., Karasik, A., Chodick, G., Pereira, D. I. A., Schou, H., Waechter, S., Göhring, U. M., & Drakesmith, H. (2023). Iron deficiency and the effectiveness of the BNT162b2 vaccine for SARS-CoV-2 infection: A retrospective, longitudinal analysis of real-world data. PLOS ONE. https://doi.org/10.1371/journal.pone.0285606

Vancouver

Tene L, Karasik A, Chodick G, Pereira DIA, Schou H, Waechter S, et al. Iron deficiency and the effectiveness of the BNT162b2 vaccine for SARS-CoV-2 infection: A retrospective, longitudinal analysis of real-world data. PLOS ONE. 2023. doi:10.1371/journal.pone.0285606

BibTeX
@article{Tene2023,
  author = {Tene, Lilac and Karasik, Avraham and Chodick, Gabriel and Pereira, Dora I A and Schou, Henrik and Waechter, Sandra and Göhring, Udo-Michael and Drakesmith, Hal},
  title = {Iron deficiency and the effectiveness of the BNT162b2 vaccine for SARS-CoV-2 infection: A retrospective, longitudinal analysis of real-world data},
  journal = {PLOS ONE},
  year = {2023},
  doi = {10.1371/journal.pone.0285606}
}
Kostenlos starten →